Send me real-time posts from this site at my email

LabCorp (LH) Bolsters RA Testing by Adding Myriad's Vectra

Laboratory Corporation of America Holdings or LabCorp LH recently completed the acquisition of select operating assets and intellectual property (IP) from Myriad Genetics' MYGN autoimmune business unit, including the Vectra rheumatoid arthritis (RA) assay. Initiated in May 2021, this acquisition strengthens LabCorp’s global position in RA testing and treatment.

The financial terms of the deal, however, were kept under wraps.

A Few Words on RA and Vectra

Rheumatoid arthritis is an autoimmune disorder and one of the most common forms of arthritis that causes painful inflammation and tissue damage in the knees, wrists, and other joints.

Vectra is a non-invasive, blood-based test capable of analyzing 12 biomarkers to measure RA activity. It combines those measures to generate a score that identifies the severity of RA inflammation and the effectiveness of the current treatment. It can also predict potential, future joint damage. This test has enabled the 5,000 practicing rheumatologists in the United States to better manage RA symptoms by providing targeted treatment and correcting ongoing treatments.

Strategic Significance of the Acquisition

The U.S. Centers for Disease Control and Prevention currently estimates that by 2040, roughly 26% of the country’s adult population will be living with doctor-diagnosed arthritis such as RA. This huge market opportunity of RA testing has enabled LabCorp to focus on this space.

According to LabCorp, Vectra and the related IP and other assets complement its prior business activity. The company noted that the integration of the Vectra testing capabilities into its legacy products offers tremendous potential. This will expand the test’s availability. Further, it will make Labcorp a single-source diagnostics solution for RA providers.

LabCorp’s Targeted Development in High-Growth Area

In its efforts to identify and expand in high-growth opportunity areas, LabCorp has acquired select operating assets and IP from Myriad. Additionally, the company agreed to acquire the outreach laboratory business of Minnesota-based North Memorial Health and will provide management services to its inpatient lab.

Image Source: Zacks Investment Research

In another high-growth area of oncology testing, in the second quarter of 2021, LabCorp launched several oncology tests, including OmniSeq INSIGHT, a pan-cancer tissue-based sequencing test for patients with advanced solid tumor cancers. It has also launched a companion diagnostic test to identify patients with non-small cell lung cancer who are eligible for a new treatment option developed by Amgen.

This apart, the company is currently exercising options to acquire the remaining stake in OmniSeq, LabCorp’s long-time oncology partner and a pioneer in solid tumor profiling.

In women’s health, another focus area, LabCorp acquired Ovia Health in August, a digital health platform to seek information and support with family planning, pregnancy, and parenting. The transaction extends Labcorp’s position as a go-to source for women’s health insights. It helps the company to advance in personalized care in this space and also enables better communication between health care providers and their patients.

Share Price Performance

The stock has outperformed its industry over the past year. It has rallied 60% compared with the industry’s 32.7% growth.

Zacks Rank and Key Picks

Currently, LabCorp carries a Zacks Rank #3 (Hold).

A few better-ranked stocks from the broader medical space are Envista Holdings Corporation NVST, and Henry Schein, Inc. HSIC, each carrying a Zacks Rank #2 (Buy). You can see the complete list of Zacks #1 Rank (Strong Buy) stocks here.

Envista Holdings has an estimated long-term earnings growth rate of 27%.

Henry Schein has a projected long-term earnings growth rate of 14%.

Tech IPOs With Massive Profit Potential

In the past few years, many popular platforms and like Uber and Airbnb finally made their way to the public markets. But the biggest paydays came from lesser-known names.

For example, electric carmaker X Peng shot up +299.4% in just 2 months. Think of it this way…

If you had put $5,000 into XPEV at its IPO in September 2020, you could have cashed out with $19,970 in November.

With record amounts of cash flooding into IPOs and a record-setting stock market, this year’s lineup could be even more lucrative.

See Zacks Hottest Tech IPOs Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Laboratory Corporation of America Holdings (LH): Free Stock Analysis Report
Henry Schein, Inc. (HSIC): Free Stock Analysis Report
Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report
Envista Holdings Corporation (NVST): Free Stock Analysis Report
To read this article on click here.
Zacks Investment Research

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue